Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: BGP-15
  • Price: $400.0/100mg $700.0/250mg $1500.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao
Related CAS#:
66611-37-8 66611-38-9
951628-79-8 72299-76-4
31849-26-0 63217-10-7
54833-55-5 104849-39-0
58681-09-7 679834-30-1

66611-37-8

66611-37-8 structure
66611-37-8 structure
  • Name: BGP-15
  • Chemical Name: N-(2-Hydroxy-3-(piperidin-1-yl)propoxy)-nicotinimidamide dihydrochloride
  • CAS Number: 66611-37-8
  • Molecular Formula: C14H24Cl2N4O2
  • Molecular Weight: 351.27200
  • Catalog: Research Areas Cardiovascular Disease
  • Create Date: 2018-11-22 08:57:34
  • Modify Date: 2024-01-08 10:54:13
  • BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively.
Name N-(2-Hydroxy-3-(piperidin-1-yl)propoxy)-nicotinimidamide dihydrochloride
Synonyms BGP-15
(Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotiniMidaMide
Description BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively.
Related Catalog
Target

PARP:120 μM (IC50)

In Vitro BGP-15 (200 μM) prevents the imatinib mesylate-induced oxidative damages, attenuates the depletion of high-energy phosphates, alters the signaling effect of imatinib mesylate by preventing p38 MAP kinase and JNK activation, and induced the phosphorylation of Akt and GSK-3beta[5].
In Vivo BGP-15 (15 mg/kg, p.o.) does not improve skeletal muscle pathology in older mdx mice[1]. In a rat model, 10 days of BGP-15 treatment greatly improves diaphragm muscle fiber function (by about 100%), although it does not reverse diaphragm atrophy. The treatment also provides protection from myosin PTMs associated with HSP72 induction and PARP-1 inhibition, resulting in improvement of mitochondrial function and content[2]. BGP-15 (15 mg/kg per day in saline) treatment has no effect in Ntg mice or an independent cohort of normal adult wild-type mice based on morphology, cardiac function and ECG parameters. Treatment with BGP-15 attenuates the increase in atrial size and lung weight. BGP-15 treatment is able to prevent or reduce episodes of arrhythmia. BGP-15 treatment is associated with a reduced PR interval in the HF+AF model[3]. BGP-15 (10 and 30 mg/kg) increases insulin sensitivity by 50% and 70%, respectively, in cholesterol-fed but not in normal rabbits. After 5 days of treatment with BGP-15, the glucose infusion rate is increased in a dose-dependent manner in genetically insulin-resistant GK rats. The most effective dose is 20 mg/kg, which shows a 71% increase in insulin sensitivity compared to control group[4].
Animal Admin Adult (appr 4 month) male HF+AF and Ntg mice are administered with BGP-15 (15 mg/kg per day in saline) for 4 weeks by oral gavage or remained untreated (oral gavage with saline or no gavage). Gavage with saline has no effect on morphological or functional parameters in the HF+AF model. Therefore, untreated mice (no gavage) and mice administered saline are combined and referred to as HF+AF control. Echocardiography and ECG studies are performed before and after treatment.
References

[1]. Kennedy TL, et al. BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle. Am J Pathol. 2016 Dec;186(12):3246-3260.

[2]. Salah H, et al. The chaperone co-inducer BGP-15 alleviates ventilation-induced diaphragm dysfunction. Sci Transl Med. 2016 Aug 3;8(350):350ra103

[3]. Sapra G, et al. The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat Commun. 2014 Dec 9;5:5705.

[4]. Literati-Nagy B, et al. Improvement of insulin sensitivity by a novel drug candidate, BGP-15, in different animal studies. Metab Syndr Relat Disord. 2014 Mar;12(2):125-31.

[5]. Sarszegi Z, et al. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.

[6]. Szabados E, et al. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase. Biochem Pharmacol. 2000 Apr 15;59(8):937-45.
Molecular Formula C14H24Cl2N4O2
Molecular Weight 351.27200
Exact Mass 350.12800
PSA 81.47000
LogP 2.80750
Storage condition 2-8°C
HS Code 2933399090
HS Code 2933399090
Summary 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Chemsrc provides CAS#:66611-37-8 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 66611-37-8 | Chemsrc address: https://m.chemsrc.com/en/baike/522874.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved